04:57 AM EST, 01/12/2026 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Sunday that it expects 2025 earnings to fall in the upper end of the $2.55 to $2.65 per diluted share range.

Analysts surveyed by FactSet expect $2.63.

The company expects revenue for the year at the lower end of the $16.8 billion to $17 billion range.

Analysts polled by FactSet expect $16.9 billion.

For 2026, the company anticipates revenue to remain flat or slightly lower compared with 2025, while for 2027, Teva said it expects low-single digit growth.

Analysts surveyed by FactSet expect revenue of $16.82 billion in 2026 and $17.25 billion in 2027.